KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $0.470 $0.470 Thursday, 17th Aug 2023 CYAD stock ended at $0.470. During the day the stock fluctuated 0% from a day low at $0.470 to a day high of $0.470.
90 days $0.470 $0.470
52 weeks $0.460 $3.07

Historical Celyad SA prices

Date Open High Low Close Volume
Feb 01, 2016 $36.00 $37.00 $34.67 $35.27 15 400
Jan 29, 2016 $37.87 $37.87 $35.11 $35.11 7 200
Jan 28, 2016 $35.94 $36.80 $33.51 $35.50 27 500
Jan 27, 2016 $37.42 $37.95 $36.44 $36.44 1 700
Jan 26, 2016 $37.02 $37.02 $37.02 $37.02 0
Jan 25, 2016 $38.05 $38.05 $37.02 $37.02 1 000
Jan 22, 2016 $37.99 $37.99 $36.42 $36.99 6 500
Jan 21, 2016 $34.42 $34.88 $33.01 $34.69 4 700
Jan 20, 2016 $33.96 $33.96 $32.00 $33.50 7 700
Jan 19, 2016 $34.88 $36.95 $34.65 $34.99 9 300
Jan 15, 2016 $37.40 $37.78 $34.30 $34.30 12 500
Jan 14, 2016 $39.49 $39.50 $38.33 $39.39 5 600
Jan 13, 2016 $42.58 $42.58 $39.51 $39.51 13 600
Jan 12, 2016 $43.64 $46.50 $40.45 $41.69 30 100
Jan 11, 2016 $47.00 $47.00 $42.18 $43.56 19 200
Jan 08, 2016 $48.94 $48.94 $46.95 $47.37 6 800
Jan 07, 2016 $46.86 $48.93 $46.86 $48.25 7 600
Jan 06, 2016 $49.45 $51.00 $49.31 $49.66 10 200
Jan 05, 2016 $52.35 $52.35 $49.24 $49.91 17 700
Click to get the best stock tips daily for free!

About Celyad SA

Celyad SA Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical... CYAD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT